Geode Capital Management LLC Lowers Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Geode Capital Management LLC reduced its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 0.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 916,081 shares of the company’s stock after selling 4,282 shares during the period. Geode Capital Management LLC owned approximately 1.91% of Amphastar Pharmaceuticals worth $34,022,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of AMPH. Wellington Management Group LLP acquired a new stake in shares of Amphastar Pharmaceuticals during the third quarter valued at $957,000. Orion Portfolio Solutions LLC acquired a new stake in Amphastar Pharmaceuticals in the third quarter valued at approximately $239,000. Barclays PLC lifted its holdings in Amphastar Pharmaceuticals by 53.3% in the 3rd quarter. Barclays PLC now owns 74,456 shares of the company’s stock worth $3,613,000 after buying an additional 25,878 shares in the last quarter. Invst LLC increased its holdings in Amphastar Pharmaceuticals by 23.6% during the 3rd quarter. Invst LLC now owns 14,390 shares of the company’s stock worth $698,000 after purchasing an additional 2,752 shares during the last quarter. Finally, Sanctuary Advisors LLC increased its position in shares of Amphastar Pharmaceuticals by 8.5% in the 3rd quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company’s stock worth $466,000 after purchasing an additional 801 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Analyst Ratings Changes

AMPH has been the subject of several recent research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Piper Sandler cut their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Friday, March 21st.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 2.2 %

Shares of AMPH stock opened at $22.99 on Thursday. The stock has a market cap of $1.10 billion, a P/E ratio of 7.66, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. The stock has a fifty day moving average price of $28.14 and a 200 day moving average price of $37.70. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.